Drugs / Adjuvanted Recombinant Zoster Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06224270 | Oct 2024 → Sep 2027 | inflammatory bowel disease | University of Wisconsin, Madison | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-10-10 | GlaxoSmithKline | Results GSK and ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024 gsk.com ↗
The Adjuvanted Recombinant Zoster Vaccine Is Effective in Preventing Herpes Zoster (HZ) Among Patients ≥50 Years of Age (YOA) with Selected Autoimmune Diseases in the United States: A Real-World Database Analysis (2018–2021) |
| 2024-02-06 | GlaxoSmithKline | Regulatory GSK’s regulatory application for Shingrix for the prevention of shingles in at-risk adults aged 18 and over accepted for review by China National Medical Products Administration gsk.com ↗
GSK plc (LSE/NYSE: GSK) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted for review the regulatory application of Shingrix (Recombinant Zoster Vaccine or RZV) for the prevention of shingles (herpes zoster) in adults aged 18 years and over at increased risk. |
| 2022-10-19 | GlaxoSmithKline | Results New data show Shingrix can provide at least 10 years of protection against shingles in adults aged 50 years and over gsk.com ↗
GSK plc (LSE/NYSE: GSK) today announced positive interim results from the ZOSTER-049 extension study showing that overall Shingrix (Zoster Vaccine Recombinant, Adjuvanted) can provide at least a decade of protection against shingles (herpes zoster) after initial vaccination. |
| 2022-10-12 | GlaxoSmithKline | Results GSK to present updates on its industry-leading infectious disease portfolio at IDWeek 2022 gsk.com ↗
Reinforcing the strength of GSK’s portfolio of vaccines, data from an extension study exploring the efficacy and safety of Shingrix over ten years will also be shared for the first time, providing further evidence on the duration of protection for adults aged 50 years and over. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-10-10 | GlaxoSmithKline | GSK and ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024 gsk.com ↗ |
| 2024-02-06 | GlaxoSmithKline | GSK’s regulatory application for Shingrix for the prevention of shingles in at-risk adults aged 18 and over accepted for review by China National Medical Products Administration gsk.com ↗ |
| 2022-10-19 | GlaxoSmithKline | New data show Shingrix can provide at least 10 years of protection against shingles in adults aged 50 years and over gsk.com ↗ |
| 2022-10-12 | GlaxoSmithKline | GSK to present updates on its industry-leading infectious disease portfolio at IDWeek 2022 gsk.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adjuvanted Recombinant Zoster Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06224270 ↗ |
| Known as | RZV | “recombinant zoster vaccine (RZV)” NCT06224270 ↗ |
| Modality | Vaccine | “The RZV vaccine is indicated for prevention of herpes zoster (HZ)” NCT06224270 ↗ |